CRP and COVID-19: Another research conducted by Marcello Di Nisio et al. found that COVID-19 patients that were treated with tocilizumab reported an improvement in elevated D-dimer levels, reduced levels of CRP, prothrombin time and aPTT, as with our outcomes.